Notice of Proposed Sale · 144
Amneal Pharmaceuticals, Inc.
AMRXNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- AMNEAL PHARMACEUTICALS, INC
- Issuer CIK
- 0001723128
- SEC file number
- 001-38485
- Phone
- 9089473120
- Person for whose account securities are to be sold
- JOHN KIELY
- Relationships to issuer
- Director
- Street
- 400 CROSSING BLVD, 3RD FLOOR
- City
- BRIDGEWATER
- State / country code
- NJ
- Postal code
- 08807
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| COMMON STOCK | 50,000 | 879,714 | 319,353,919 | 08/13/2026 | NASDAQ | MERRILL LYNCH |
Broker / market maker — proposed row 1, entry 1
- Name
- MERRILL LYNCH
- Street
- 157 CHURCH ST, FL 26
- City
- NEW HAVEN
- State / country code
- CT
- Postal code
- 06510
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| COMMON STOCK | 05/05/2021 | EQUITY COMPENSATION | ISSUER | 15,289 | N | 05/05/2021 | EQUITY COMPENSATION |
| COMMON STOCK | 05/10/2024 | EQUITY COMPENSATION | ISSUER | 34,711 | N | 05/10/2024 | EQUITY COMPENSATION |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 08/13/2026
- Signed
- JOHN KIELY
Company context
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For additional information, please visit amneal.com and follow us on LinkedIn.